| dc.contributor.author | Hansen, S. | |
| dc.contributor.author | De Bono, J. S. | |
| dc.contributor.author | Ozguroglu, M. | |
| dc.contributor.author | Machiels, J. H. | |
| dc.contributor.author | Shen, L. | |
| dc.contributor.author | Sartor, A. O. | |
| dc.contributor.author | Oudard, S. | |
| dc.date.accessioned | 2021-03-05T09:51:13Z | |
| dc.date.available | 2021-03-05T09:51:13Z | |
| dc.date.issued | 2011 | |
| dc.identifier.citation | Sartor A. O. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Shen L., De Bono J. S. , "Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.", JOURNAL OF CLINICAL ONCOLOGY, cilt.29, 2011 | |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_9fe91693-1006-4008-b745-0f3c2272fafb | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/107294 | |
| dc.identifier.uri | https://doi.org/10.1200/jco.2011.29.15_suppl.4525 | |
| dc.language.iso | eng | |
| dc.subject | Onkoloji | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. | |
| dc.type | Makale | |
| dc.relation.journal | JOURNAL OF CLINICAL ONCOLOGY | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 29 | |
| dc.identifier.issue | 15 | |
| dc.contributor.firstauthorID | 200459 | |
